THERAPY DOSSIER · th-014086a371f6

Scopoletin (SC)

Nutraceutical · Scopoletin, a coumarin phytochemical.

Evidence & regulatory context

Mechanism: Scopoletin, a coumarin phytochemical.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29595543 ↗2018Reported benefit

Protective Effect of Scopoletin Against Cerulein-Induced Acute Pancreatitis and Associated Lung Injury in Mice.

MouseChemical/toxinSwiss miceMaleIntraperitoneal10 mg/kg1 hour after the first of six hourly cerulein injections (post-injury treatment)

Model: Cerulein-induced acute pancreatitis with associated lung injury

Scopoletin attenuated the severity of cerulein-induced acute pancreatitis and associated lung injury, reducing histological damage, myeloperoxidase activity, serum amylase, pancreatic and pulmonary proinflammatory cytokines, hydrogen sulfide and NF-kB activation, and mast cell activation markers, c…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…